Quick answers
- What is Dichlorphenamide used for?
- The FDA-approved label (Keveyis, Xeris Pharmaceuticals, Inc., March 4, 2026) says: “KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Dichlorphenamide have a boxed warning?
- No. None of the 4 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Dichlorphenamide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Dichlorphenamide been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Dichlorphenamide?
- 4 companies list prescription products of Dichlorphenamide in the FDA NDC Directory, including Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Ltd and Rising Pharma Holdings, Inc..
What Dichlorphenamide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants
— FDA label: Keveyis, Xeris Pharmaceuticals, Inc., effective March 4, 2026. Read the full label on DailyMed →
The FDA has 4 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 4 FDA labels for this medicine have a boxed warning.
Forms and how it is given
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Torrent Pharmaceuticals Limited1 product
- Cycle Pharmaceuticals Ltd1 product
- Rising Pharma Holdings, Inc.1 product
- Xeris Pharmaceuticals, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA011366 DARANIDE, KEVEYIS | Xeris | July 22, 1958 | 16, latest November 22, 2019 2019: Efficacy · 2015: Efficacy · 2013: Manufacturing (CMC) |
Generic approvals (2)
- ANDA215924Torrent · December 29, 2022
- ANDA218783Rising · November 18, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 197594, 1661799, 2677447 |
|---|---|
| SPL set ID of the quoted label | d30a87b9-90fb-35b2-e053-2995a90aea2c |
| FDA labels (SPL) | 4 |
| FDA applications | NDA011366, 2 ANDA |
| Active ingredients (FDA) | DICHLORPHENAMIDE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Keveyis, Xeris Pharmaceuticals, Inc., effective March 4, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →